TECHWIRE 30
(CIX: WRAL30)  1,098.65  down arrow-1.93  (-0.18 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NQ: Apple)  100.57  up arrow+0.04  (0.04 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NY: QUINTILES)  56.05  down arrow-0.08  (-0.14 %)  Updated: 06:40 PM EDT, Aug 20 2014
(OP: BASF SE)  101.47  down arrow-0.66  (-0.65 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NQ: BioCryst)  13.09  down arrow-0.31  (-2.31 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NQ: BioDelivery)  13.89  down arrow-0.12  (-0.86 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NQ: CEMP)  9.49  down arrow-0.23  (-2.37 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NQ: Cisco Systems)  24.71  up arrow+0.07  (0.28 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NQ: Cree)  45.39  down arrow-0.14  (-0.3 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NQ: DARA)  1.27  down arrow-0.01  (-0.78 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NY: EMC CORPORATION)  29.70  down arrow-0.19  (-0.64 %)  Updated: 06:40 PM EDT, Aug 20 2014
(NQ: Extreme Networks)  5.28  up arrow+0.04  (0.76 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NQ: FB)  74.81  down arrow-0.48  (-0.64 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NY: GLAXOSMITHKLINE)  47.81  up arrow+0.46  (0.97 %)  Updated: 06:40 PM EDT, Aug 20 2014
(NQ: GOOG)  584.49  down arrow-2.37  (-0.4 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NY: IBM)  190.10  up arrow+0.03  (0.02 %)  Updated: 06:40 PM EDT, Aug 20 2014
(NY: LH)  106.15  up arrow+0.35  (0.33 %)  Updated: 06:40 PM EDT, Aug 20 2014
(OP: Lenovo Group)  30.35  down arrow-0.92  (-2.93 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NY: MRK)  59.48  up arrow+0.57  (0.97 %)  Updated: 06:40 PM EDT, Aug 20 2014
(NQ: Microsoft Corp)  44.95  down arrow-0.38  (-0.84 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NQ: NTAP)  40.97  up arrow+0.14  (0.33 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NY: NOVARTIS AG)  88.60  down arrow-0.03  (-0.03 %)  Updated: 06:40 PM EDT, Aug 20 2014
(OP: Novozymes A/S)  45.12  down arrow-1.48  (-3.18 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NY: PFIZER)  28.89  down arrow-0.05  (-0.17 %)  Updated: 06:40 PM EDT, Aug 20 2014
(NQ: Pozen)  7.65  down arrow-0.21  (-2.67 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NY: RED HAT)  61.68  down arrow-0.86  (-1.38 %)  Updated: 06:40 PM EDT, Aug 20 2014
(NQ: BBRY)  10.16  up arrow+0.31  (3.15 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NQ: Salix)  157.18  down arrow-3.62  (-2.25 %)  Updated: 08:10 PM EDT, Aug 20 2014
(NQ: SQI)  15.15    (0 %)  Updated: 08:10 PM EDT, Aug 20 2014

Posts tagged “Novartis”

Updated July 17

Premium Lock Startup says aloha to name after Hawaii protests; FDA-Pozen update; new Tantalus exec; Apple $400M ebook settlement; Novartis earnings; Visa's new system

Bulldog In today's Bulldog wrapup of life science and technology news: A L.A. company changes its name after protests in Hawaii; FDA accepts Pozen application; smart grid firm Tantalus in Raleigh names COO; Apple faces $400M ebook settlement; Novartis earnings; and Visa launches new online payment system.

July 16

Premium Lock Yahoo earnings fall; N.C. Solar Center's new name; Novartis-Google 'Glass' contacts; Cree expands; Sling's new devices

Bulldog In today's Bulldog wrapup of technology and life science news: Yahoo takes a hit; N.C. Solar Center gets a new name; Novartis teams with Google for "Glass" contacts; Cree adds space; Sling's new devices.

June 26

Premium Lock North Carolina emerges as leader in world vaccine development

Pandemic In the third part of a series offering an overview of North Carolina's global prominence as a home for life science companies, the N.C. Biotechnology Center's Jim Shamp provides an overview of vaccine development.

June 17

Premium Lock Holly Springs' Novartis plant symbolizes healthcare revolution

The revolution has nothing to do with its proximity to the July 4 Independence Day holiday. Rather, it's in the way Flucelvax from Novartis is made at the plant. It's the first flu vaccine produced without antibiotics and preservatives, using a unique biological "soup" called cell culture.

Novartis plant in Holly Springs Novartis plant in Holly Springs

June 17

Premium Lock Novartis gets FDA nod to produce new kind of flu vaccine at Holly Springs plant

Novartis plant in Holly Springs The FDA licensed pharmaceutical firm Novartis' Holly Springs location on Monday to produce cell-culture influenza vaccines. It's the first such facility in the U.S.

April 23

Premium Lock Government contracts likely mean immunity for big Novartis vaccine plant

Plans for pharmaceutical giants Novartis, GlaxoSmithKline and Eli Lilly to swap business lines may have shaken up the stock market Tuesday, but work at a Novartis flu vaccine plant in Holly Springs hummed along, and local officials said they expect it to remain that way.

Novartis plant in Holly Springs Novartis plant in Holly Springs

Updated April 22

Premium Lock Glaxo CEO: Major deals to 'improve long-term earnings'

GSK's top executive Andrew Witty says the multiple deals announced early Tuesday with Novartis promise to deliver "broadly sustainable sourced sales growth and improve long-term earnings."

Andrew Witty    Andrew Witty

Updated April 22

Premium Lock Novartis swaps businesses with GSK, plans to sell Holly Springs plant

Novartis Two drug giants with major operations in the Triangle, Novartis and GlaxoSmithKline, are swapping businesses in two major deals. Meanwhile, Novartis plans to sell its huge Holly Springs plant in a separate deal and also strikes an agreement to sell its animal health business to Eli Lilly. No layoffs are planned, Novartis says.

Updated April 22

Premium Lock Novartis-GSK deals slide show: How they change Novartis

Drug giants Novartis and GlaxoSmithKline each offered investors online presentations that spell out graphically how the deals announced Tuesday will affect each company. Here's a look at three key slides from the Novartis presentation.

Novartis gains GSK's oncology portfolio Novartis gains GSK's oncology portfolio

Updated April 22

Premium Lock GSK-Novartis deals slide show: How they change GSK

Drug giants GlaxoSmithKline and Novartis each offered investors online presentations that spell out graphically how the deals announced Tuesday will affect each company. Here's a look at three key slides from the GSK presentation.

GSK's proposed new vaccine portfolio GSK's proposed new vaccine portfolio

January 14

Premium Lock Square worth $5B?; SAS lands big deal; PayPal's new service; Merck stock jumps; BlackBerry's new sales chief

Bulldog In our Bulldog blog's tech and life science news update: Square offers shares at $135 each; SAS signs Europe's leading drugstore chain; PayPal testing new service; Merck shares jump on drug news; BlackBerry names new sales chief and lands $250M in investment.

January 9

Premium Lock Report: Novartis looks to deal vaccine, animal health businesses to Merck

Novartis reportedly is in negotiations with fellow drug giant Merck about a $10 billion asset swap that would include the Novartis human vaccines and animal health businesses. Novartis operates a huge vaccine in Holly Springs and is building an R&D center in RTP.

Novartis plant in Holly Springs Novartis plant in Holly Springs

Updated October 22, 2013

Premium Lock SAS ranks No. 2, Quintiles No. 18 in global Great Place to Work list

Several technology and life science firms with a major presence in North Carolina crack the top 25 in the annual World's Best Multinational Workplaces ranking. NetApp, Cisco, Google, Microsoft and Novartis all make the list.

World's Best Multinational Workplaces World's Best Multinational Workplaces

October 9, 2013

Premium Lock Novartis' North Carolina vaccine team takes up arms

Employees rolled up their sleeves at the $1 billion Novartis Holly Springs vaccine manufacturing facility this week and joined the global throngs marking a revolution in the fight against flu.

Flucelvax package photo, courtesy of Novartis. Flucelvax package photo, courtesy of Novartis.

Updated October 9, 2013

Premium Lock Drug giant Novartis to launch research lab in RTP

Novartis, which operates a huge vaccine manufacturing facility in Holly Springs, is going to hire up to 100 people to staff a new research and development lab in Research Triangle Park. Some jobs also will be moved to RTP from Massachusetts.

Inside the Novartis plant Inside the Novartis plant

Updated August 19, 2013

Premium Lock Chairman: Novartis, which has huge plant in Holly Springs, to review business units

International drug maker Novartis will start a strategic review of its units as early as next week and would consider a $10 billion purchase among options for bolstering the business, says new Chairman Joerg Reinhardt.

Novartis plant in Holly Springs Novartis plant in Holly Springs

Updated July 17, 2013

Premium Lock Novartis slashes ex-chairman's golden parachute to $6M from $78M

Novartis CEO Joe Jimenez, left, and former Chairman Daniel Vasella Novartis AG has cut former Chairman Daniel Vasella's payout to less than a tenth of the original $78 million, a sum that had helped galvanize support for a Swiss referendum on limiting executive pay.

Updated July 17, 2013

Premium Lock As blood pressure generic fails to materialize, Novartis ups full-year guidance

Novartis Europe's biggest drugmaker says it expects to lose $2.7 billion in sales to generic competition this year, 23 percent less than it previously forecast, as it continues to benefit from Ranbaxy Laboratories's failure to market a copycat version of the Diovan hypertension drug.

June 28, 2013

Premium Lock SAS, Quintiles slip on Europe 'Best Companies' list

Great Place To Work logo Several high-tech and life science firms based in North Carolina or who have a large presence here crack the "Best Multinationals" to work for list in Europe. But several of them also drop somewhat from the 2012 list.

February 22, 2013

Premium Lock Novartis chairman may keep working with firm as a consultant

Daniel Vasella Daniel Vasella, who is stepping down as chairman of international drug firm Novartis and decided not to accept a $78 million non-compete agreement, is now talking with the company about a consulting role.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Scroll